Aequus Pharmaceuticals Inc. (AQS.V)
- Previous Close
0.0050 - Open
0.0050 - Bid --
- Ask 0.0050 x --
- Day's Range
0.0050 - 0.0050 - 52 Week Range
0.0050 - 0.0400 - Volume
100,000 - Avg. Volume
71,486 - Market Cap (intraday)
663,170 - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 16, 2025 - May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.aequuspharma.ca--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AQS.V
View MorePerformance Overview: AQS.V
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AQS.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AQS.V
View MoreValuation Measures
Market Cap
663.17k
Enterprise Value
7.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.14
Price/Book (mrq)
--
Enterprise Value/Revenue
12.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-157.74%
Return on Equity (ttm)
--
Revenue (ttm)
584.24k
Net Income Avi to Common (ttm)
-2.18M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
50.24k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-995.37k